Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

Angina Pectoris Clinical Trial

— T89 phase 2  

Official title:

A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00797953
• Other study ID #: T89-005-0003-US
• Status: Completed
• Phase: Phase 2
• First received: November 24, 2008
• Last updated: December 10, 2012
• Start date: February 2007
• Est. completion date: January 2010

Study information

• Verified date: December 2012
• Source: Tasly Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

Description:

T89 is a modernized and industrialized version of a traditional Chinese herbal medicine. T89 was approved for marketing as a drug, for the treatment of chronic stable angina pectoris due to coronary heart disease, by the State Food and Drug Administration (SFDA) of China in 1993. There were more than 2 billion doses have been prescribed or used, in about 10,000,000 subjects, in short or long-term administration worldwide.

The product is also marketed, as a drug, in Russia, South Korea, Mongolia, Singapore, Vietnam, and South Africa. The current study is to determine the anti-angina effect and dose response of T89 in patients with chronic stable angina pectoris in the United States.

T89 consists of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active constitutes, and using Borneol as transporting enhancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: January 2010
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patient must be between the ages of 18 and 80 years.

2. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.

3. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation.

4. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes.

5. Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)

6. Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0

7. All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued.

8. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards.

9. Patient must be able to give voluntary written informed consent.

Exclusion Criteria:

1. With contraindication to perform treadmill Exercise Tolerance Test (ETT).

2. Pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could interfere with exercise electrocardiograph interpretation.

3. Clinically significant arrhythmias or atrioventricular conduction block greater than first degree.

4. Clinically significant co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.

5. History of congestive heart failure, unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.

6. History of bleeding diathesis, or is on warfarin.

7. Implanted pacemaker.

8. Aspirin and/or statins started less than 14 days prior to the signing of informed consent.

9. Pregnancy or lactation.

10. Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and allow only short-acting nitroglycerin and one beta-blocker or calcium channel blocker.

11. Clinical trials/experimental medication:

• Participation in any other clinical trial or receipt of an investigational drug within 90 days prior to initial visit.

• Those patients unable, in the opinion of the investigator, to comply fully with the trial requirements.

• Previous participation in this study.

12. Substance abuse. Patients with a recent history (within the last 2 years) of alcoholism or known drug dependence.

13. Patient is a family member or relative of the study site staff.

Related Conditions & MeSH terms

• Angina Pectoris
• Angina, Stable

Intervention

Drug:
• T89
A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.

Locations

Country	Name	City	State
United States	Alexandria Cardiology Clinic	Alexandria	Louisiana
United States	Great Lakes Research Group, Inc	Bay City	Michigan
United States	Robert M. Karns, A Medical Corporation	Beverly Hills	California
United States	Three Rivers Medical Associates	Columbia	South Carolina
United States	Inland Heart Doctors	Corona	California
United States	East Texas Cardiology	Houston	Texas
United States	Northwest Houston Cardiology	Houston	Texas
United States	Sunrise Medical Research	Lauderdale Lakes	Florida
United States	Gemini Scientific, LLC	Madison	Wisconsin
United States	Cardiovascular Research Center of South Florida	Miami	Florida
United States	National Clinical Research-Norfolk, Inc	Norfolk	Virginia
United States	Oklahoma Cardiovascular & Hypertension	Oklahoma	Oklahoma
United States	Northwest Heart Center	Tomball	Texas
United States	Paradigm Clinical, Inc.	Tucson	Arizona
United States	Marc Kozinn Associates	Williamsville	New York

Sponsors (1)

Lead Sponsor	Collaborator
Tasly Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Exercise Duration (TED) change from screen baseline value in Exercise Tolerance Test (ETT) on Standard Bruce Protocol at trough drug levels at the end of the 4th and 8th week of treatment compared to placebo.		12 weeks
Secondary	Frequency of weekly angina episodes		12 weeks

External Links

•   Manufacture